• Applied Uses of ddATP in DNA Synthesis Termination Workflows

  2026-06-26

  Unlock precision in DNA synthesis control with ddATP, a chain-terminating nucleotide analog indispensable for Sanger sequencing and DNA repair pathway interrogation. This guide details protocol optimization, troubleshooting, and emerging insights from oocyte genomic studies, equipping molecular biologists for advanced applications.

• MAPK10-Driven KRT16 Degradation Suppresses NSCLC Metastasis

  2026-06-26

  This study uncovers a phosphorylation-dependent mechanism by which MAPK10 phosphorylates keratin 16 (KRT16), promoting its ubiquitination and degradation via RNF213, thereby suppressing non-small cell lung cancer (NSCLC) metastasis. These insights highlight the MAPK10/KRT16/RNF213 axis as a promising therapeutic and prognostic target for metastatic NSCLC.

• Ferrostatin-1 (Fer-1): Precision Inhibition of Ferroptosis i

  2026-06-25

  Explore how Ferrostatin-1 (Fer-1) enables precise, selective inhibition of ferroptosis through advanced redox modulation. This article delivers a unique, in-depth analysis of Fer-1's scientific utility, bridging molecular mechanisms with innovative applications in cancer and neurology.

• Optimizing Epigenetic Assays with RG108: Evidence-Driven Gui

  2026-06-25

  This article provides scenario-driven, data-backed guidance for integrating RG108 (SKU A1913), a small-molecule DNA methyltransferase inhibitor, into biomedical research workflows. Drawing on validated protocols and comparative vendor analysis, we address common challenges in epigenetic gene regulation studies, emphasizing how RG108 from APExBIO enhances experimental reliability and interpretability.

• Carbapenemase Gene Transmission in CREC: Guangdong Multi-Hos

  2026-06-24

  This study systematically characterizes the prevalence, diversity, and plasmid-mediated transmission of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong during the COVID-19 era. Its findings reveal extensive multidrug resistance and highly efficient gene transfer, with important implications for infection control and molecular epidemiology.

• Plerixafor (AMD3100): Strategic Leverage in CXCR4-Targeted R

  2026-06-23

  This thought-leadership article elucidates the mechanistic underpinnings and translational potential of Plerixafor (AMD3100) as a benchmark CXCR4 antagonist in cancer metastasis inhibition, hematopoietic stem cell mobilization, and immune modulation. By integrating recent comparative evidence—including the pivotal Khorramdelazad et al. study on novel CXCR4 inhibitors in colorectal cancer—and offering strategic guidance, it empowers translational researchers to optimize study design and stay at the forefront of CXCR4-targeted innovation.

• Degarelix Acetate in Prostate Cancer Research: Applied Workf

  2026-06-23

  Degarelix acetate offers unparalleled selectivity as a GnRH receptor antagonist, enabling rapid and sustained hormone suppression in both in vitro and in vivo models. This guide details evidence-driven protocols, advanced applications, and troubleshooting strategies to optimize experimental outcomes in prostate cancer and endocrine research.

• Syringin Enhances Sunitinib Efficacy via EGFR/PI3K/Akt Block

  2026-06-22

  This study demonstrates that Syringin, a natural phenylpropanoid glycoside, inhibits renal cell carcinoma (RCC) cell proliferation and migration while promoting apoptosis. Notably, Syringin enhances the efficacy of sunitinib by blocking the EGFR/PI3K/Akt pathway, offering a mechanistically validated strategy to overcome drug resistance in targeted RCC therapy.

• CTOP as a Precision Probe: Unraveling Central μ-Opioid Pathw

  2026-06-22

  Explore how CTOP, a potent μ-opioid receptor antagonist, enables innovative dissection of central opioid signaling circuits in pain research. This article delivers unique insights into optimizing experimental design and interpretation, integrating the latest advances in mechanistic neuropharmacology.

• Reversine: Protocol and Workflow Guide for Aurora Kinase Inh

  2026-06-21

  Reversine is a small molecule Aurora kinase inhibitor designed for the precise study of mitotic regulation and cell cycle checkpoints in cancer biology research. It is best suited for controlled in vitro and in vivo applications focused on cancer cell proliferation inhibition and apoptosis induction in cancer cells, particularly within the context of the Aurora kinase signaling pathway. Use is not recommended outside research environments or for diagnostic/medical purposes due to solubility and storage constraints.

• 2-NBDG Fluorescent Glucose Uptake: Advanced Assay Workflows

  2026-06-20

  2-NBDG, a fluorescent glucose analog, transforms glucose metabolism assays by enabling rapid, quantitative, and live-cell analysis of glucose uptake. Its compatibility with flow cytometry and microscopy brings high sensitivity to fields ranging from diabetes research to tumor metabolism studies, with APExBIO setting the standard for workflow reliability.

• Cyclic di-GMP as an Antitoxin: Regulating Biofilm Persistenc

  2026-06-19

  Liao et al. (2024) identify cyclic di-GMP as a unique small-molecule antitoxin that governs genome stability and antibiotic persistence in bacterial biofilms through regulation of a HipH-based toxin-antitoxin module. This discovery clarifies the mechanistic link between early biofilm development and increased persister cell frequency, offering new targets for combating chronic infections.

• Cyclic di-GMP: Intracellular Second Messenger in Biofilm & I

  2026-06-19

  Cyclic di-GMP acts as a pivotal intracellular second messenger in bacteria, regulating biofilm formation and persistence. In mammalian systems, it directly activates the STING pathway, making it central to immune modulation research and cancer immunotherapy studies. This article details the molecular mechanisms, benchmarks, and practical parameters for deploying APExBIO's high-purity cyclic di-GMP in advanced workflows.

• Phenytoin and AED-Induced Inhibition of Human Serum Paraoxon

  2026-06-18

  This study systematically evaluated the inhibitory effects of key antiepileptic drugs, including phenytoin (5,5-diphenylimidazolidine-2,4-dione), on purified human serum paraoxonase-1 (hPON1) activity in vitro. The findings reveal differential, noncompetitive inhibition profiles among the AEDs, with important implications for understanding drug-enzyme interactions in neurological and cardiovascular contexts.

• Dynamic Remodeling of Damaged CNS Myelin Sheaths Revealed by

  2026-06-18

  This study demonstrates that myelin sheaths in the central nervous system (CNS) possess a previously underestimated capacity to withstand damage and dynamically remodel, rather than inevitably being lost. The findings provide mechanistic insight into early myelin pathology and highlight neuronal activity as a modifiable factor influencing myelin recovery, with direct implications for demyelination research and therapeutic strategies.

573 records 1/39 page Next 12345 下5页 Last page